Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf Benz

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cancers|March 11, 2023
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective StudyNora-Medea Messerich, Narasimha Rao Uda, Thomas Volken, et al.
Cancer Epidemiology|January 6, 2017
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012Nicolas Bonadies, Anita Feller, Alicia Rovo, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Haematologica|November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Cancers|July 2, 2021
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision MedicineIoannis Chanias, Kristina Stojkov, Gregor Th Stehle, et al.
Hemasphere|June 24, 2022
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)Axel Rüfer, Hubert Angermann, Rudolf Benz, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cancers|March 11, 2023
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective StudyNora-Medea Messerich, Narasimha Rao Uda, Thomas Volken, et al.
Cancer Epidemiology|January 6, 2017
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012Nicolas Bonadies, Anita Feller, Alicia Rovo, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Haematologica|November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Cancers|July 2, 2021
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision MedicineIoannis Chanias, Kristina Stojkov, Gregor Th Stehle, et al.
Hemasphere|June 24, 2022
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)Axel Rüfer, Hubert Angermann, Rudolf Benz, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Pageof 4